Netherlands-based firm Thirona has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the latest version of the company's AI-powered CT analysis software, LungQ.
LungQ 4 extends the capabilities of previous versions by improving peripheral airway segmentation, estimating chronic perfusion defects from CT, and improving post-treatment detection of endobronchial implants, according to the firm. The software uses perfusion approximation analysis (PXT) to apply deep learning to estimate approximate chronic perfusion defects directly from CT images. This provides quantitative data for anatomical regions to support treatment target selection in lung volume reduction therapy and advances quantitative imaging in functional lung assessment.
PXT is already available for clinical use in Europe, the UK, and Australia, Thirona said.
